Anti-GPC3 Antibody CDR Optimization for Stronger Tumor Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-GPC3 antibodies face issues of low binding affinity and suboptimal cytotoxic activity, particularly at the cellular level, limiting their effectiveness in targeting GPC3-positive cancers.
Innovation Solution
Development of an anti-GPC3 antibody or antigen-binding fragment with optimized heavy and light chain complementarity-determining regions (CDRs) and potential mutations at specific positions, along with a novel GPC3 antigen epitope peptide to enhance binding affinity and cytotoxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-GPC3 antibodies are used, then they can bind to GPC3 and exhibit some cytotoxic activity, but their binding affinity is insufficient and cellular cytotoxic effects are suboptimal
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the CDR sequences of the antibody to improve binding affinity. Specifically, the patent identifies and optimizes the complementarity-determining regions (CDRs) of the heavy and light chains, making targeted amino acid substitutions to enhance the antibody's binding capacity to GPC3 while maintaining manufacturability
Solution Approach 2:
The patent replaces conventional antibody development approaches with a rational design strategy based on structural analysis and computational modeling. Instead of relying solely on traditional hybridoma methods or empirical screening, the patent uses structure-based antigen-antibody interaction analysis to guide CDR optimization, thereby improving binding affinity through a more precise and efficient methodology
2Reliability
If existing anti-GPC3 antibodies are used, then they can target GPC3-positive cells, but their cellular cytotoxic activity is insufficient
Solution Approach 1:
The patent applies local quality by focusing optimization efforts specifically on the CDR regions of the antibody, which are the local structures directly responsible for antigen binding and subsequent cytotoxic activity. By making targeted amino acid substitutions in the CDR1, CDR2, and CDR3 regions of both heavy and light chains, the patent enhances the local binding interface quality to improve overall cellular cytotoxic effects
Solution Approach 2:
The patent creates a composite antibody structure by combining optimized CDR regions from different sources or designing chimeric CDR sequences that integrate favorable properties from multiple antibody variants. This composite approach allows the antibody to achieve superior cytotoxic activity by combining the strengths of different CDR configurations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized anti-GPC3 antibody demonstrates strong binding capacity and improved cytotoxicity, potentially enhancing therapeutic efficacy against GPC3-positive cancers.
Implementation Method 1
Antibodies binding to GPC3 have been identified to exhibit cell growth-inhibitory effects through antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activities
Implementation Method 2
Upon binding to a tumor cell surface antigen, the antibody component is endocytosed into the cell
Implementation Method 3
Subsequently, the ADC is broken down in lysosomes, releasing the active cytotoxic payload
Data Source
Figure 1A~2
Figure 3
Figure 4
AI summary
Provided in the present invention are an anti-GPC-3 antibody and an antigen-binding fragment thereof, and also provided are a polynucleotide encoding the antibody, an expression vector and a host cell for expressing the antibody, and a method for preparing the antibody. In addition, further provided in the present invention are a pharmaceutical composition comprising the antibody and the use of the antibody in the preparation of a drug for treating cancers.